Literature DB >> 26751890

Cystic echinococcosis in Southern Israel.

Shalom Ben-Shimol, Orli Sagi, Ohad Houri, Elina Bazarsky, Anat Berkowitz, Shlomi Bulkowstein, Chiya Barrett, David Greenberg.   

Abstract

The aim of this retrospective, population-based study was to characterize demographically and clinically cystic-echinococcosis (CE) in southern Israel, between 2005 and 2012. Newly-diagnosed (nd-CE) and past-diagnosed (pd-CE, diagnosed before the study) cases were defined. Two populations live in southern-Israel, receiving medical treatment at a single hospital: the Jewish and the Bedouin populations (resembling resource-rich and resource-poor populations, respectively). 126 CE cases were identified; 55 nd-CE and 71 pd-CE. Mean annual nd-CE incidence per 100,000 in the Bedouin and Jewish populations were 2.7 ± 1.2 and 0.4 ± 0.3, respectively (P<0.001). None of the Bedouin and 86.5% of the Jewish patients were born outside Israel. Liver and lung involvement were recorded in 85.7% and 15.1% of overall-CE, respectively. Abdominal pain, cough, fever, eosinophilia and asymptomatic disease were documented in 63.6%, 32.7%, 27.3%, 41.5% and 12.7% of nd-CE, respectively. Serology sensitivity for first test and any positive test were 67.3% and 83.3%, respectively. Computed tomography, ultrasonography and X-ray diagnosis were documented in 79.2%, 58.4% and 17.0% of overall-CE, respectively, with ultrasonography mainly used in liver-CE and X-ray in lung-CE. Treatment included surgery and albendazole in 50.0% and 55.3% of CE, respectively. We conclude that CE is endemic in southern-Israel among the Bedouin population, while disease is probably mainly imported in the Jewish population. Liver involvement and eosinophilia rates were high compared with those of other endemic regions, possibly due to differences in the timing of diagnosis. These findings may help developing treatment and prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26751890     DOI: 10.1515/ap-2016-0024

Source DB:  PubMed          Journal:  Acta Parasitol        ISSN: 1230-2821            Impact factor:   1.440


  3 in total

1.  Clinical characteristics and antibodies against Echinococcus granulosus recombinant antigen P29 in patients with cystic echinococcosis in China.

Authors:  Jia Tao; Xiancai Du; Kejun Liu; Chan Wang; Yongxue Lv; Minglei Wang; Zhiqi Yang; Jihui Yang; Shasha Li; Changyou Wu; Minghao Li; Wei Zhao
Journal:  BMC Infect Dis       Date:  2022-07-12       Impact factor: 3.667

2.  The clinical burden of human cystic echinococcosis in Palestine, 2010-2015.

Authors:  Amer Al-Jawabreh; Suheir Ereqat; Kamal Dumaidi; Abdelmajeed Nasereddin; Hanan Al-Jawabreh; Kifaya Azmi; Nahed Al-Laham; Moath Nairat; Adriano Casulli; Husni Maqboul; Ziad Abdeen
Journal:  PLoS Negl Trop Dis       Date:  2017-07-03

3.  Human Cystic Echinococcosis in Lebanon: A Retrospective Study and Molecular Epidemiology.

Authors:  Gaelle Joanny; Maria Grazia Cappai; Francesca Nonnis; Claudia Tamponi; Giorgia Dessì; Naunain Mehmood; Julien Dahdah; Chadi Hosri; Antonio Scala; Antonio Varcasia
Journal:  Acta Parasitol       Date:  2021-07-15       Impact factor: 1.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.